In line with this picture, baseline levels of the immune markers CD8 (a potential surrogate marker for cytotoxic tumor-infiltrating T-lymphocytes) and PD-L1 had a moderate predictive impact on pCR under anti-HER2 therapy, whether measured by IHC or by mRNA assessment. This evidence concerns the gene CD274 and neoplasm.